CorroHealth Announces Strategic Partnership with Patient Square Capital
Get Alerts CG Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 13.4%
EPS Growth %: +5.2%
Join SI Premium – FREE
"Since its inception in 2019, CorroHealth has grown into a technology and clinically led health care RCM platform," said CorroHealth CEO
Patient Square Partner
Carlyle has been the majority investor in CorroHealth since 2019 and a predecessor business since 2017.
The transaction is expected to close by the end of the year. Barclays and TripleTree are serving as co-lead financial advisors to CorroHealth; Latham & Watkins is serving as legal counsel to CorroHealth and Carlyle; and Kirkland & Ellis is serving as legal counsel to Patient Square.
About CorroHealth
CorroHealth is a leading provider of clinically led healthcare analytics and technology-driven solutions, dedicated to positively impacting the financial performance for physicians, hospitals, and health plans. With over 15,000 employees worldwide, CorroHealth offers integrated solutions, proven expertise, intelligent technology, and scalability to address needs across the entire revenue cycle. Our global presence extends over 10 locations, including
About Patient Square
Patient Square Capital is a dedicated health care investment firm with approximately
About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With
Media Contacts:
CorroHealth:
[email protected]
Patient Square:
Prosek Partners
[email protected]
Carlyle:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/corrohealth-announces-strategic-partnership-with-patient-square-capital-302285395.html
SOURCE CorroHealth
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
- Rocket Marketing Named #1 Roofing Marketing Company for 2026
- New Benchmark Reveals Invicti as the Best Agentic Pentesting Tool in Tests
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
The Carlyle Group, BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share